Summary of COVID-19 deuremidevir studies
Studies
Meta Analysis
Hide extended summaries
1,296 patient deuremidevir early treatment RCT: 15% faster recovery (p=0.01) and 24% improved viral clearance (p=0.006).
RCT 1,369 patients with mild-to-moderate COVID-19 showing significantly faster time to sustained clinical symptom resolution (median 10.9 days vs 12.9 days) with VV116 compared to placebo. VV116 was given as 0.6g BID day 1 followed by 0.3g BID on days 2-5.
Nov 2023, The Lancet Infectious Diseases, https://www.sciencedirect.com/science/article/pii/S1473309923005777, https://c19p.org/fan3
Prospective 136 hospitalized mild to moderate COVID-19 patients in China, showing faster viral clearance with VV116 treatment. 60 patients received VV116 300mg twice daily for 5 days plus standard care, while 76 patients received only standard care. VV116 was generally safe, with only mild adverse events reported.
Jun 2022, Emerging Microbes & Infections, https://www.tandfonline.com/doi/full/10.1080/22221751.2022.2078230, https://c19p.org/shen4
1,296 patient deuremidevir early treatment RCT: 15% faster recovery (p=0.01) and 24% improved viral clearance (p=0.006).
RCT 1,369 patients with mild-to-moderate COVID-19 showing significantly faster time to sustained clinical symptom resolution (median 10.9 days vs 12.9 days) with VV116 compared to placebo. VV116 was given as 0.6g BID day 1 followed by 0.3g BID on days 2-5.
Nov 2023, The Lancet Infectious Diseases, https://www.sciencedirect.com/science/article/pii/S1473309923005777, https://c19p.org/fan3
2. Shen et al., An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants
136 patient deuremidevir early treatment study: 11% faster viral clearance (p=0.07).Prospective 136 hospitalized mild to moderate COVID-19 patients in China, showing faster viral clearance with VV116 treatment. 60 patients received VV116 300mg twice daily for 5 days plus standard care, while 76 patients received only standard care. VV116 was generally safe, with only mild adverse events reported.
Jun 2022, Emerging Microbes & Infections, https://www.tandfonline.com/doi/full/10.1080/22221751.2022.2078230, https://c19p.org/shen4
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.